Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ADorable-2 long-term lebrikizumab extension in pediatric atopic dermatitis
2022-501478-21-00Phase 3Authorised
- Sponsor
- Eli Lilly and Company
- Start
- Mar 2024
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 13
01
Overview
Phase 3, open-label, single-arm trial of lebrikizumab in atopic dermatitis (AD), sponsored by Eli Lilly and Company. Primary endpoint: Percentage of participants discontinued from study treatment due to adverse events. Planned start Mar 2024; status: authorised.
02
Drugs
lebrikizumab
03
Conditions
atopic dermatitis (AD)
Beyond the preview
Go deeper on 2022-501478-21-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2022-501478-21-00.